138 results
8-K
ITCI
Intra-Cellular Therapies, Inc.
7 Aug 24
Intra-cellular Therapies Reports Second Quarter 2024
7:49am
as other executive level employees as well as long-term disability
insurance and reimbursement for reasonable business expenses. The initial term
8-K
EX-10.2
ITCI
Intra-Cellular Therapies, Inc.
7 Aug 24
Intra-cellular Therapies Reports Second Quarter 2024
7:49am
with long-term disability insurance.
3.4 Reimbursement of Certain Expenses. The Company will reimburse Executive for reasonable business expenses
8-K
EX-99.1
ITCI
Intra-Cellular Therapies, Inc.
7 Aug 24
Intra-cellular Therapies Reports Second Quarter 2024
7:49am
initiating CAPLYTA and monitor periodically during long-term treatment.
Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases
8-K
EX-99.1
ITCI
Intra-Cellular Therapies, Inc.
18 Jun 24
Other Events
7:37am
CAPLYTA and monitor periodically during long-term treatment.
Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases). Complete blood
8-K
EX-99.1
d37if7syctqh66 4m5u4
7 May 24
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7:40am
8-K
EX-1.1
7a9pic8f
18 Apr 24
Entry into a Material Definitive Agreement
5:25pm
424B5
3sjzpto4aiimkm5ol6
18 Apr 24
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.2
rkz186fpbmzj u36
16 Apr 24
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:40pm
424B5
3ejsqyiwz2iiq
16 Apr 24
Prospectus supplement for primary offering
4:37pm
8-K
EX-99.1
8nrp2dzsnf36 8o
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
EX-99.1
nwo8eyh bg1ks
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
8-K
EX-99.1
l1bct o1xi4ncjxsblq
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
8-K
EX-99.1
66mobq39v9o20ueytkr
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am